RxDoctor Payments Data

Marisa Buonanno-Hamrah, NP

Women's Health · West Orange, NJNPI 1215104963

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $833, 7.6 times the $110 reported in 2021. Among women's health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,306in general payments, 2019–2025

Across 127 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$367
  • Merck$282
  • Astellas Pharma US Inc$258
  • Sumitomo Pharma America, Inc.$224
  • GSK$166
  • AbbVie$149
  • plus $860 from 19 others

What the payments were for

  • Food & beverage$2,15493%
  • Education$1527%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,306 in reported general payments places this provider in the 95th percentile of 182 women's health providers in New Jersey.

See all women's health providers in New Jersey

Medicare billing

Part B allowed, 2024
$57,108
Medicare patients
302
Services billed
554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImvexxyEstradiol42$16,036
MyrbetriqMirabegron13$9,190
PremarinEstrogens, Conjugated28$9,183
Estradiol90$7,099
YuvafemEstradiol25$4,571
Letrozole94$1,640
Norethindrone Acetate16$777
Clobetasol Propionate11$606
Estradiol (Once Weekly)Estradiol11$483
Imiquimod13$357
Triamcinolone Acetonide64$356
Medroxyprogesterone Acetate26$294
Metronidazole13$214
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$154
Fluconazole20$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Therapeuticsmd, Inc.Imvexxy$13$16,03642 claims
Astellas Pharma US IncMyrbetriq$258$9,19013 claims
PfizerPremarin$139$9,18328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 women's health providers in New Jersey.

Other women's health in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →